141 related articles for article (PubMed ID: 30793153)
1. A platinum(iv) prodrug to defeat breast cancer through disrupting vasculature and inhibiting metastasis.
Guo Y; Zhang S; Yuan H; Song D; Jin S; Guo Z; Wang X
Dalton Trans; 2019 Mar; 48(11):3571-3575. PubMed ID: 30793153
[TBL] [Abstract][Full Text] [Related]
2. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.
Ma ZY; Wang DB; Song XQ; Wu YG; Chen Q; Zhao CL; Li JY; Cheng SH; Xu JY
Eur J Med Chem; 2018 Sep; 157():1292-1299. PubMed ID: 30195239
[TBL] [Abstract][Full Text] [Related]
3. Nitric oxide-releasing platinum(IV) prodrug efficiently inhibits proliferation and metastasis of cancer cells.
Dai Y; Zhu Y; Cheng J; Shen J; Huang H; Liu M; Chen Z; Liu Y
Chem Commun (Camb); 2020 Nov; 56(90):14051-14054. PubMed ID: 33103676
[TBL] [Abstract][Full Text] [Related]
4. Monochalcoplatin: An Actively Transported, Quickly Reducible, and Highly Potent Pt
Ma L; Wang N; Ma R; Li C; Xu Z; Tse MK; Zhu G
Angew Chem Int Ed Engl; 2018 Jul; 57(29):9098-9102. PubMed ID: 29806087
[TBL] [Abstract][Full Text] [Related]
5. Coordination-driven self-assembly of a Pt(iv) prodrug-conjugated supramolecular hexagon.
Yue Z; Wang H; Li Y; Qin Y; Xu L; Bowers DJ; Gangoda M; Li X; Yang HB; Zheng YR
Chem Commun (Camb); 2018 Jan; 54(7):731-734. PubMed ID: 29303526
[TBL] [Abstract][Full Text] [Related]
6. A dual-targeting hybrid platinum(IV) prodrug for enhancing efficacy.
Xiao H; Yan L; Zhang Y; Qi R; Li W; Wang R; Liu S; Huang Y; Li Y; Jing X
Chem Commun (Camb); 2012 Nov; 48(87):10730-2. PubMed ID: 23012698
[TBL] [Abstract][Full Text] [Related]
7. Phospholipid-mimic oxaliplatin prodrug liposome for treatment of the metastatic triple negative breast cancer.
Feng B; Zhou F; Lu W; Wang D; Wang T; Luo C; Wang H; Li Y; Yu H
Biomater Sci; 2017 Jul; 5(8):1522-1525. PubMed ID: 28406499
[TBL] [Abstract][Full Text] [Related]
8. Alternative mechanism of action of the DNP Pt
Krasnovskaya O; Spector D; Erofeev A; Gorelkin P; Akasov R; Skvortsov D; Trigub A; Vlasova K; Semkina A; Zyk N; Beloglazkina E; Majouga A
Dalton Trans; 2021 Jun; 50(23):7922-7927. PubMed ID: 34037020
[TBL] [Abstract][Full Text] [Related]
9. Towards rational design of RAD51-targeting prodrugs: platinum
Zhang S; Yuan H; Guo Y; Wang K; Wang X; Guo Z
Chem Commun (Camb); 2018 Oct; 54(83):11717-11720. PubMed ID: 30229259
[TBL] [Abstract][Full Text] [Related]
10. Engineering liposomal nanoparticles of cholesterol-tethered amphiphilic Pt(iv) prodrugs with prolonged circulation time in blood.
Datta P; Bang S; Yue Z; Beach T; Stilgenbauer M; Wang H; Bowers DJ; Kurokawa M; Xiao H; Zheng YR
Dalton Trans; 2020 Jun; 49(24):8107-8113. PubMed ID: 32490446
[TBL] [Abstract][Full Text] [Related]
11. Novel hypoxia-targeting Pt(iv) prodrugs.
Xu Z; Zhao J; Gou S; Xu G
Chem Commun (Camb); 2017 Mar; 53(26):3749-3752. PubMed ID: 28303266
[TBL] [Abstract][Full Text] [Related]
12. A cancer specific oxaliplatin-releasing Pt(iv)-prodrug.
Reshetnikov V; Arkhypov A; Julakanti PR; Mokhir A
Dalton Trans; 2018 May; 47(19):6679-6682. PubMed ID: 29708261
[TBL] [Abstract][Full Text] [Related]
13. A Dual Killing Strategy: Photocatalytic Generation of Singlet Oxygen with Concomitant Pt
Norman DJ; Gambardella A; Mount AR; Murray AF; Bradley M
Angew Chem Int Ed Engl; 2019 Oct; 58(40):14189-14192. PubMed ID: 31397963
[TBL] [Abstract][Full Text] [Related]
14. Tirapazamine-embedded polyplatinum(iv) complex: a prodrug combo for hypoxia-activated synergistic chemotherapy.
Guo D; Xu S; Yasen W; Zhang C; Shen J; Huang Y; Chen D; Zhu X
Biomater Sci; 2020 Jan; 8(2):694-701. PubMed ID: 31777870
[TBL] [Abstract][Full Text] [Related]
15. Platinum(IV) prodrugs multiply targeting genomic DNA, histone deacetylases and PARP-1.
Xu Z; Hu W; Wang Z; Gou S
Eur J Med Chem; 2017 Dec; 141():211-220. PubMed ID: 29031068
[TBL] [Abstract][Full Text] [Related]
16. Hybrid inorganic (nonporous silica)/organic (alginate) core-shell platform for targeting a cisplatin-based Pt(IV) anticancer prodrug.
Ravera M; Gabano E; Bonzani D; Zanellato I; Arrais A; Cantamessa S; Biggiogera M; Osella D
J Inorg Biochem; 2018 Dec; 189():185-191. PubMed ID: 30312905
[TBL] [Abstract][Full Text] [Related]
17. A Quadruple-Action Platinum(IV) Prodrug with Anticancer Activity Against KRAS Mutated Cancer Cell Lines.
Petruzzella E; Braude JP; Aldrich-Wright JR; Gandin V; Gibson D
Angew Chem Int Ed Engl; 2017 Sep; 56(38):11539-11544. PubMed ID: 28759160
[TBL] [Abstract][Full Text] [Related]
18. Redirecting Cisplatin and Doxorubicin to Mitochondria Affords Highly Effective Platinum
Muhammad N; Cai-Ping T; Nasreen S; Mao ZW
Chem Asian J; 2021 Aug; 16(16):2276-2279. PubMed ID: 34231967
[TBL] [Abstract][Full Text] [Related]
19. Efficient co-delivery of a Pt(IV) prodrug and a p53 activator to enhance the anticancer activity of cisplatin.
Ma R; Wang Y; Yan L; Ma L; Wang Z; Chan HC; Chiu SK; Chen X; Zhu G
Chem Commun (Camb); 2015 May; 51(37):7859-62. PubMed ID: 25854514
[TBL] [Abstract][Full Text] [Related]
20. Pt(IV) Anticancer Prodrugs - A Tale of Mice and Men.
Gibson D
ChemMedChem; 2021 Jul; 16(14):2188-2191. PubMed ID: 33928760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
